Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

In a report released on February 14, Christophe dombu from Kepler Capital maintained a Buy rating on Hyloris Pharmaceuticals SA (52U – Research Report), with a price target of €16.00.

The Sackler family and Purdue Pharma, the maker of the addictive painkiller oxycontin, have reached a $7.4 billion settlement with a bipartisan coalition of 15 states for fueling the opioid crisis ...

Feb. 10, 2025 — Rapid weight loss affects muscle mass and can increase the risk of osteoporosis. But now there is good news for people taking weight loss medication who may be at risk. A new ...

A nurse prepares to administer a malaria vaccine to an infant at the health center in Datcheka, Cameroon January 22, 2024. REUTERS/Desire Danga Essigue/File Photo The U.S. government's foreign aid ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

The pharmaceutical industry is at a pivotal moment. Artificial intelligence (AI) is shifting from improving processes to reshaping disease treatment and care delivery. Early adopters are seeing ...

The change has effectively pushed out many foreign pharmaceutical companies that do not want to compete against Chinese companies willing to sell their drugs at rock-bottom prices. Now ...

JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

Evolus said on Thursday the U.S. drug regulator has approved its two new anti-wrinkle gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau. US FDA approves Evolus ...